Clinical trial
Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia
NCT00021983 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00021983 |
|---|---|
| Title | Immunotoxin Therapy in Treating Patients With Hairy Cell Leukemia |
| Official title | Phase I Study of BL22, a Recombinant Immunotoxin for Treatment of CD22+ Leukemias and Lymphomas |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological |
| Interventions | BL22 immunotoxin |
| Start date | Dec 1, 1998 |
| First posted | Dec 12, 2003 |
| Last update posted | Apr 29, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: